Fapon Biopharma Unveils Innovative CD3/TCR VHH TCE Platform at CEO Forum
Fapon Biopharma recently announced its participation in the 19th Annual European Life Sciences CEO Forum held at the Hilton Zurich Airport Hotel on March 4-5, 2026. In this key industry event, Dr. Kaiqing Zhang, the Associate Director of Business and Corporate Development, will present a pioneering approach in cancer immunotherapy.
Titled 'Unlocking the Next Generation of TCEs: Fapon's Human/Cyno Cross-Reactive CD3/TCR VHH Platform', the presentation will focus on the innovative features of their proprietary T-cell engager (TCE) platform. This advanced platform addresses significant hurdles traditionally associated with multi-specific antibodies, providing a fresh and more effective method for treatment.
Fapon's CD3/TCR VHH-based platform leverages cross-reactive single-domain antibodies, specifically designed to work seamlessly in the human immune system as well as in cynomolgus monkeys. This dual reactivity is crucial as it decreases potential safety risks in early clinical phases and expedites the translational journey into therapeutic applications.
The platform offers distinct advantages by allowing a modular design that’s adaptable, enabling a 'plug-and-play' model with optimized activation kinetics. As a result, Fapon's technology can effectively target two significant therapeutic markets:
1. Oncology: Fapon's T-cell redirection technology aims to combat various solid and hematological tumors, engineered for improved activation kinetics to reduce the risk associated with cytokine release.
2. Autoimmune Diseases: The company’s platform can design potent T-cell engagers capable of inducing deep B-cell depletion, thus resetting the immune functionality for patients facing refractoriness in conventional therapies.
The cornerstone of Fapon’s technology rests upon a suite of cross-species CD3/TCR VHHs, which display varying binding affinities to the human immune system and non-human primates. Such functional versatility is expected to maintain efficacy while elevating safety during preclinical assessments. Early evaluations yielded promising findings, demonstrating not just superior efficacy but also predictable pharmacokinetics and pharmacodynamics in animal trials.
Fapon Biopharma is now actively pursuing strategic partnerships for co-development and licensing of this cutting-edge platform. Companies interested in collaboration, especially those involved in advancing cancer therapeutics and autoimmune conditions, are encouraged to reach out through their official communication channels.
With a commitment to address unmet medical needs, Fapon Biopharma is recognized for its specialized work in the discovery and development of biologics designed to treat cancer and autoimmune diseases. The company utilizes state-of-the-art technology, fortifying its drug discovery platforms that encompass various therapeutic strategies. From antibody discovery technologies to innovative drug formulations, Fapon aims to deliver safe, effective, and accessible treatments to a broader population.
The rich pipeline of leading drug candidates developed by Fapon showcases its relentless dedication to innovation, ensuring patients receive the most advanced therapeutic options.
Titled 'Unlocking the Next Generation of TCEs: Fapon's Human/Cyno Cross-Reactive CD3/TCR VHH Platform', the presentation will focus on the innovative features of their proprietary T-cell engager (TCE) platform. This advanced platform addresses significant hurdles traditionally associated with multi-specific antibodies, providing a fresh and more effective method for treatment.
Fapon's CD3/TCR VHH-based platform leverages cross-reactive single-domain antibodies, specifically designed to work seamlessly in the human immune system as well as in cynomolgus monkeys. This dual reactivity is crucial as it decreases potential safety risks in early clinical phases and expedites the translational journey into therapeutic applications.
The platform offers distinct advantages by allowing a modular design that’s adaptable, enabling a 'plug-and-play' model with optimized activation kinetics. As a result, Fapon's technology can effectively target two significant therapeutic markets:
1. Oncology: Fapon's T-cell redirection technology aims to combat various solid and hematological tumors, engineered for improved activation kinetics to reduce the risk associated with cytokine release.
2. Autoimmune Diseases: The company’s platform can design potent T-cell engagers capable of inducing deep B-cell depletion, thus resetting the immune functionality for patients facing refractoriness in conventional therapies.
The cornerstone of Fapon’s technology rests upon a suite of cross-species CD3/TCR VHHs, which display varying binding affinities to the human immune system and non-human primates. Such functional versatility is expected to maintain efficacy while elevating safety during preclinical assessments. Early evaluations yielded promising findings, demonstrating not just superior efficacy but also predictable pharmacokinetics and pharmacodynamics in animal trials.
Fapon Biopharma is now actively pursuing strategic partnerships for co-development and licensing of this cutting-edge platform. Companies interested in collaboration, especially those involved in advancing cancer therapeutics and autoimmune conditions, are encouraged to reach out through their official communication channels.
With a commitment to address unmet medical needs, Fapon Biopharma is recognized for its specialized work in the discovery and development of biologics designed to treat cancer and autoimmune diseases. The company utilizes state-of-the-art technology, fortifying its drug discovery platforms that encompass various therapeutic strategies. From antibody discovery technologies to innovative drug formulations, Fapon aims to deliver safe, effective, and accessible treatments to a broader population.
The rich pipeline of leading drug candidates developed by Fapon showcases its relentless dedication to innovation, ensuring patients receive the most advanced therapeutic options.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.